Moscow City Clinical Hospital No.51

Moscow 121309

0 studies enrolling now · 5 studies all time

What they study most

Chronic Thromboembolic Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease, Pulmonary Arterial Hypertension

Studies at this site

• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension — Stopped early
• A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease — Completed
• A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease — Stopped early
• A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment — Stopped early